Analysis of the clinical variables associated with recrudescence after malignant hyperthermia reactions

Anesthesiology

Volumn 106, Issue 5, 2007, Pages 901-906

  Burkman, James M ^a   Posner, Karen L ^a   Domino, Karen B ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DANTROLENE; DESFLURANE; ENFLURANE; HALOTHANE; ISOFLURANE; MUSCLE RELAXANT AGENT; SEVOFLURANE; SUXAMETHONIUM;

ADOLESCENT; ADULT; AGED; ANESTHESIA COMPLICATION; ARTICLE; BODY BUILD; CHI SQUARE TEST; CHILD; CLINICAL FEATURE; COMPARATIVE STUDY; CONTROLLED STUDY; DEMOGRAPHY; DISEASE ASSOCIATION; END TIDAL CARBON DIOXIDE TENSION; FEMALE; GENERAL ANESTHESIA; HUMAN; HYPERTHERMIA; INFORMATION RETRIEVAL; LUNG VENTILATION; MAJOR CLINICAL STUDY; MALE; MALIGNANT HYPERTHERMIA; MEDICAL PARAMETERS; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; MUSCLE; MUSCLE MASS; MUSCLE RIGIDITY; NORTH AMERICA; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; RECURRENT DISEASE; REGISTER; RESPIRATORY ACIDOSIS; SCORING SYSTEM; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; STUDENT T TEST; SYMPTOMATOLOGY; TACHYCARDIA; TREATMENT OUTCOME; UNIVARIATE ANALYSIS;

ADOLESCENT; ADULT; AGED; BODY TEMPERATURE; CASE-CONTROL STUDIES; CHILD; CHILD, PRESCHOOL; DANTROLENE; FEMALE; HUMANS; INFANT; INFANT, NEWBORN; LOGISTIC MODELS; MALE; MALIGNANT HYPERTHERMIA; MIDDLE AGED; RECURRENCE; TIME FACTORS;

EID: 34247595476     PISSN: 00033022     EISSN: 15281175     Source Type: Journal    
DOI: 10.1097/01.anes.0000265148.86566.68     Document Type: Article

References (31)

1. ++ regulating proteins. Curr Mol Med 2002; 2:347-69
2. Litman RS, Rosenberg H: Malignant hyperthermia: Update on susceptibility testing. JAMA 2005; 293:2918-24
3. Struk A, Lehmann-Horn F, Melzer W: Voltage-dependent calcium release in human malignant hyperthermia muscle fibers. Biophys J 1998; 75:2402-10
4. Dirksen RT, Avila G: Distinct effects on Ca2+ handling caused by malignant hyperthermia and central core disease mutations in RyR1. Biophys J 2004; 87:3193-204
5. Sei Y, Sambuughin NN, Davis EJ, Sachs D, Cuenca PB, Brandom BW, Tautz T, Rosenberg H, Nelson TE, Muldoon SM: Malignant hyperthermia in North America: Genetic screening of the three hot spots in the type I ryanodine receptor gene. ANESTHESIOLOGY 2004; 101:824-30
6. Weiss RG, O'Connell KM, Flucher BE, Allen PD, Grabner M, Dirksen RT: Functional analysis of the R1086H malignant hyperthermia mutation in the DHPR reveals an unexpected influence of the III-IV loop on skeletal muscle EC coupling. Am J Physiol Cell Physiol 2004; 287:1094-102
7. Paul-Pletzer K, Yamamoto T, Bhat MB, Ma J, Ikemoto N, Jimenez LS, Morimoto H, Williams PG, Parness J: Identification of a dantrolene-binding sequence on the skeletal muscle ryanodine receptor. J Biol Chem 2002; 277:34918-23
8. Nelson TE, Lin M, Zapata-Sudo G, Suda RT: Dantrolene sodium can increase or attenuate activity of skeletal muscle ryanodine receptor calcium release channel: Clinical implications. ANESTHESIOLOGY 1996; 84:1368-79
9. Pollock AN, Langton EE, Couchman K, Stoweli KM, Waddington M: Suspected malignant hyperthermia reactions in New Zealand. Anaesth Intensive Care 2002; 30:453-61
10. Mathieu A, Bogosian AJ, Ryan JF, Crone RK, Crocker D: Recrudescence after survival of an initial episode of malignant hyperthermia. A NESTHESIOLOGY 1979; 51:454-5
11. Fletcher R, Blennow G, Olsson AK, Ranklev E, Tornebrandt K: Malignant hyperthermia in a myopathic child: Prolonged postoperative course requiring dantrolene. Acta Anaesthesiol Scand 1982; 26:435-8
12. Rutberg H, Hakanson E: Malignant hyperthermia: Clinical course and metabolic changes in two patients. Acta Anaesthesiol Scand 1986; 30:211-4
13. Morrison AG, Serpell MG: Malignant hyperthermia during prolonged surgery for tumour resection. Eur J Anaesthesiol 1998; 15:114-7
14. Short JA, Cooper CM: Suspected recurrence of malignant hyperthermia after post-extubation shivering in the intensive care unit, 18 h after tonsillectomy. Br J Anaesth 1999; 82:945-7
15. Larach MG: The North American Malignant Hyperthermia Registry. Anesthesiol Clin North Am 1994; 12:607-20
16. Larach MG, Localio AR, Allen GC, Denborough MA, Ellis FR, Gronert GA, Kaplan RF, Muldoon SM, Nelson TE, Ording H, Rosenberg H, Waud BE, Wedel DJ: A clinical grading scale to predict malignant hyperthermia susceptibility. ANESTHESIOLOGY 1994; 80:771-9
17. Iaizzo PA, Kehler CH, Carr RJ, Sessler DI, Belani KG: Prior hypothermia attenuates malignant hyperthermia in susceptible swine. Anesth Analg 1996; 82:803-9
18. Nelson TE: Porcine malignant hyperthermia: Critical temperatures for in vivo and in vitro responses. ANESTHESIOLOGY 1990; 73:449-54
19. Gronert GA, Milde JH, Taylor SR: Porcine muscle responses to carbachol, α- and β-adrenoceptor agonists, halothane or hyperthermia. J Physiol 1980; 307:319-33
20. Denborough M, Hopkinson KC, O'Brien RO, Foster PS: Overheating alone can trigger malignant hyperthermia in piglets. Anaesth Intensive Care 1996; 24:348-54
21. Lichtman AD, Oribabor C: Malignant hyperthermia following systemic rewarming after hypothermic cardiopulmonary bypass. Anesth Analg 2006; 102:372-5
22. Tobin JR, Jason DR, Challa VR, Nelson TE, Sambuughin N: Malignant hyperthermia and apparent heat stroke (research letter). JAMA 2001; 286:168-9
23. Ochiai R, Toyoda Y, Nishio I, Takeda J, Sekiguchi H, Fukushima K, Kohda E: Possible association of malignant hyperthermia with sevoflurane anesthesia. Anesth Analg 1992; 74:616-8
24. Ducart A, Adnet P, Renaud B, Riou B, Krivosic-Horber R: Malignant hyperthermia during sevoflurane administration. Anesth Analg 1995; 80:609-11
25. 2+ release from the sarcoplasmic reticulum of skeletal muscle. ANESTHESIOLOGY 1999; 91:179-86
26. 2+ release from the sarcoplasmic reticulum of mammalian skeletal muscle. ANESTHESIOLOGY 2000; 93:832-6
27. Flewellen EH, Nelson TE, Jones WP, Arens JF, Wagner DL: Dantrolene dose response in awake man: Implications for management of malignant hyperthermia. ANESTHESIOLOGY 1983; 59:275-80
28. Kolb ME, Horne ML, Martz R: Dantrolene in human malignant hyperthermia. ANESTHESIOLOGY 1982; 56:254-62
29. Lerman J, McLeod ME, Strong HA: Pharmacokinetics of intravenous dantrolene in children. ANESTHESIOLOGY 1989; 70:625-9
30. Podranski T, Bouillon T, Schumacher PM, Taguchi A, Sessler DI, Kurz A: Compartmental pharmacokinetics of dantrolene in adults: Do malignant hyperthermia association dosing guidelines work? Anesth Analg 2005; 101:1695-9
31. Pessah IN, Lynch C III, Gronert GA: Complex pharmacology of malignant hyperthermia. ANESTHESIOLOGY 1996; 84:1275-9